Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for CAMPATH
- Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation
- TMLI and Alemtuzumab for Treatment of Sickle Cell Disease
- Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide
- Autologous Transplant Targeted Against Crohn's
- Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation
- Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia
- CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients
- Precision Dosing of Alemtuzumab
- Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor
- Cyclophosphamide and Alemtuzumab In Lymphoma
- Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease
- Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides
- Cyclosporine Plus Methotrexate or Alemtuzumab
- Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease
- A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors
- High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease
- Treatment of Familiar Lymphohistiocytosis
- Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis
- CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
- Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma
- Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
- Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction
- Islet Cell Transplant for Type 1 Diabetes
- Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
- Belatacept Early Steroid Withdrawal Trial
- Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis
- Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis
- Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders
- Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects
- Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
- Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
- Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)
- Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL)
- Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection
- Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)
- Alemtuzumab and Rituximab in Aplastic Anemia
- Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis
- Study Cyclosporine (CsA) Versus Tacrolimus (Tacro) After Campath Induction in Kidney Transplantation
- Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients
- Advanced MRI Measures of Repair in Alemtuzumab Treated Patients
- Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies
- Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab
- Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation
- Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)
- Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols
- Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy
- Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders
- CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
- Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation
- Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease
- Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
- Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
- Haploidentical PBMC Transplant for Severe Congenital Anemias
- Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
- Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
- Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies
- Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
- Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL)
- Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
- Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
- Mycophenolate Mofetil Maintenance Therapy for Liver Transplantation
- A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia
- Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
- Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation
- Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
- Alemtuzumab and Cyclosporine for the Prevention of Graft vs Host Disease After Stem Cell Transplants
- Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia
- Alemtuzumab + Rituximab Consolidation in CLL
- Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias
- Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
- Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
- Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation
- Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)
- T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
- Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation
- Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism
- Alemtuzumab and CHOP in T-cell Lymphoma
- Reduced Intensity AlloTransplant For Osteopetrosis
- A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.
- Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
- Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia
- Campath Maintenance in Chronic Lymphocytic Leukemia
- Oral Paricalcitol in Kidney Transplant Recipients
- Evaluating the Use of RFT5-dgA to Deplete Alloreactive Cells Prior to Haploidentical Stem Cell Transplantation
- Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT
- Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath
- Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation
- Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders
- Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
- Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath
- Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia
- Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease
- T-Reg Cell Kinetics, Stem Cell Transplant, REGALE
- Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP
- Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO
- Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia
- Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
- Belatacept Post Depletional Repopulation to Facilitate Tolerance
- Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP
- Oral Valganciclovir Versus Valacyclovir
- Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma
- Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
- Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders
- Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
- Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
- Non-Myeloablative Allogeneic Stem Cell Transplantation
- CFAR Study in Patients With Chronic Lymphocytic Leukemia
- Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
- Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma
- Campath in Chronic GVHD
- The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias
- Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia
- Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H
- Alemtuzumab and Pentostatin In T-cell Neoplasms
- Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen
- The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL
- Donor Stem Cell Transplantation for Congenital Immunodeficiencies
- Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML
- Stem Cell Transplant in Sickle Cell Disease and Thalassemia
- T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
- "A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52) Therapy in Primary Renal Allograft Transplantation"
- Alemtuzumab (Campath ) to Treat T-Large Granular Lymphocyte Leukemia
- Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic Leukemia
- Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation
- CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas
- Simultaneous Pancreas-kidney Transplantation With Campath Protocol
- Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation
- Islet Cell Transplantation Alone and CD34+ Donor Bone Marrow Cell Infusion in Type 1 Diabetes Mellitus
- Low Dose Sirolimus or CsA-Based Maintenance Immunosuppression After Induction With Campath-1 in Kidney Transplantation
- Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism
- Hematopoietic Stem Cell Support in Vasculitis
- Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
- Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia
- Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia
- CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation
- Safety in Immunomodulatory Functions of Alemtuzumab (Campath) in Pediatric Kidney Transplantation Recipients
- Phase 2 Fludarabine, Cytoxan and FCCAM
in Untreated B-Cell Chronic Lymphocytic Leukemia - To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning
- A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome
- A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation
- A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus
- Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation
- Alemtuzumab to Treat Severe Aplastic Anemia
- Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
- Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation
- Stem Cell Transplant for Immunologic or Histiocytic Disorders
- Stem Cell Transplant for Hemoglobinopathy
- Islet Transplantation Using Campath-1H and Infliximab Induction
- Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation
- A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression
- A Trial to Assess Campath-1H and Tacrolimus Followed by Immunosuppression Withdrawal in Liver Transplantation
- Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia
- Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma
- Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome
- Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
- Effectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft Rejection
- Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia
- Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease
- Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
- Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients
- Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
- Campath-1H + FK506 and Methylprednisolone for GVHD
- Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients
- Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia
- Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
- Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia
- Alemtuzumab to Treat Sporadic Inclusion Body Myositis
- Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults
- Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL
- Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
- Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders
- Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML
- Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
- Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
- Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
- Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias
- Stem Cell Transplant for Hematologic Diseases
- Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases
- Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases
- Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma
- Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
- Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H
- Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
- Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
- Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
- Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
- Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies
- Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
- Safety and Efficacy of Campath in Nonmyeloablative Transplantation
- Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
- Treatment of Chronic Granulomatous Disease With Allogeneic Stem Cell Transplantation Versus Standard of Care
- Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia
- Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
- Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
- Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys
Clinical trials list
click for details